Document is current
Any future updates will be listed below
-
Authors
Passali, Moschoula https://orcid.org/0000-0003-2759-7903
Galea, Ian https://orcid.org/0000-0002-1268-5102
Knudsen, Maria Højberg https://orcid.org/0000-0003-0432-1488
Lau, Laurie Chi
Cramer, Stig Præstekjær https://orcid.org/0000-0003-2959-2161
Frederiksen, Jette Lautrup https://orcid.org/0000-0003-1661-7438
-
Funding
Funding for this research was provided by:
Scleroseforeningen (A38270)
Scleroseforeningen (A40110)
Scleroseforeningen (A42545)
National Hospital
- License Information
-
More Information
Article History
Received: 22 June 2024
Revised: 15 July 2024
Accepted: 16 July 2024
First Online: 25 July 2024
Declarations
:
: The authors have no conflicts of interest related to this study. M. Passali received funding from the Danish Multiple Sclerosis Society. I. Galea received funding from Merck-Serono, Novartis and The Binding Site. M.H. Knudsen received funding from Sanofi Genzyme and the Danish Multiple Sclerosis Society and non-financial support from Merck. S.P. Cramer received funding from Sanofi Genzyme and the Danish Multiple Sclerosis Society. J. Frederiksen served on scientific advisory boards for and received funding for travel related to these activities as well as honoraria from Merck Serono, Sanofi-Aventis, Roche, Novartis and Chiesi.
: The study was conducted in accordance with the 1964 Declaration of Helsinki and its later amendments. Participants signed written informed consent form before study participation in the clinical trial with protocol number H-17019986 and our biomarker study with protocol number H-4–2014-095. Both protocols were approved by Copenhagen’s Regional Committee on Health Research Ethics.
